fbpx
Research finds cannabis terpenes as a promising for pain therapies

Research finds cannabis terpenes as a promising for pain therapies

managing pain with cannabis terpenes

When it comes to the medicinal and therapeutic properties of Cannabis sativa, an unsolved mystery is whether there exists an “entourage effect,” whereby the pain-relieving effects of the plant as a whole are greater than any of its individual parts. 

New research from the University of Arizona Health Sciences has found evidence that favors the entourage effect theory and positions Cannabis terpenes, the part of the plant that provides flavor and aroma, as a promising new target for pain therapies that would require lower doses and produce fewer side effects.

A lot of people are taking cannabis and cannabinoids for pain. We’re interested in the concept of the entourage effect, with the idea being that maybe we can boost the modest pain-relieving efficacy of THC and not boost the psychoactive side effects, so you could have a better therapeutic.”

– John Streicher, PhD, lead researcher, member of the UArizona Health Sciences Comprehensive Pain and Addiction Center and associate professor of pharmacology at the College of Medicine – Tucson

Terpenes are aromatic compounds found in many plants and are the basic component in essential oils. The terpene linalool, for example, gives lavender its distinctive floral scent. In addition to terpenes, Cannabis sativa contains naturally occurring compounds known as cannabinoids, the most well-known of which are cannabidiol, or CBD, and tetrahydrocannabinol, or THC, the psychoactive component of cannabis.

Researchers found that Cannabis terpenes, when used by themselves, mimic the effects of cannabinoids, including a reduction in pain sensation. When combined with cannabinoids, the pain-relieving effects were amplified without an increase in negative side effects. The paper, “Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity,” was published in Scientific Reports.

Missouri Medical Marijuana Sales Set Record in June

Missouri Medical Marijuana Sales Set Record in June

missouri medical marijuana sets new sales record

Missouri’s medical marijuana industry topped $70 million in cumulative sales, including nearly $16.4 million in June, according to the Missouri Department of Health and Senior Services.

Eight months after the state’s first dispensary opened in October 2020, 126 dispensaries operate throughout the state. Those dispensaries, plus manufacturers, transporters, and laboratories, total 201 medical marijuana facilities in the state.

“This is essentially Missouri’s newest twenty-first century industry,” Alan Zagier, a representative from the Missouri Medical Cannabis Trade Association, said. “Now we’re really at the moment when rubber hits the road, and we’re really starting to see the results of all this hard work our members have put in.”

Zaiger said the industry contributes to a post-COVID economy.

“The benefit extends to not just cannabis patients but also to the workforce,” he said. “This is a real shot in the arm for lots of communities across the state. These are real, tangible jobs.”

A total of 375 facilities have been licensed to handle medical marijuana by DHSS.

“We’re not just talking about dispensaries in our urban centers in St. Louis and Kansas City, and even there in mid-Missouri,” Zaiger said. “We’re talking about dispensaries in places like Hayti and Caruthersville.”

Shangri-La Dispensaries is one of those facilities, with dispensaries in Columbia and Jefferson City.

“Business is phenomenal,” Michael Lafrieda, the Chief Operating Officer for Shangri-La, said. The dispensary sees “several hundred [customers] a day. On some of the longer holiday weekends, a couple thousand people.”

Lafrieda said his customers range in age from teens to eighties. Zaiger said that nearly 121,000 Missourians have been approved as medical marijuana patients, with many more applications.

“For the sake of comparison,” Zaiger said. “Illinois has about 12.6 million residents, so that’s more than double of Missouri. And even now, several years into their program, they currently only have 55 licensed retail outlets open, so that’s less than half of the number that we have open in less than a year’s time.”

California Lawmakers Approve Bill To Legalize Psychedelics Possession

California Lawmakers Approve Bill To Legalize Psychedelics Possession

California psychedelics possession has been legalized by legislators

A California Assembly committee on Tuesday approved a Senate-passed bill to legalize possession of psychedelics, clearing its first major hurdle in the chamber.

The Assembly Public Safety Committee advanced the legislation, sponsored by Sen. Scott Wiener (D), in a 5-3 vote.

This comes one day after the senator held a rally with military veterans, law enforcement and health officials to build support for the proposal.

SB 519 would remove criminal penalties for possessing or sharing numerous psychedelics—including psilocybin mushrooms, DMT, ibogaine, LSD and MDMA—for adults 21 and older.

The sponsor supported a committee amendment that removed ketamine from the list of psychedelics included in the reform. That’s in addition to a series of technical revisions that were made to the legislation.

The full Senate approved the bill earlier this month, and it still has two more Assembly panel stops—the Public Health and Appropriations Committees—before moving to the floor and then, potentially, to the governor’s desk.

“Under SB 519, we will no longer arrest people and incarcerate them for the simple personal possession of psychedelics for personal or shared use,” Wiener told the committee on Tuesday. “That’s really the question here: Do we believe that we should be arresting someone because they possess psychedelics for personal use? I don’t think we should. Frankly, I think most people don’t think we should be doing that.”

A California Assembly committee on Tuesday approved a Senate-passed bill to legalize possession of psychedelics, clearing its first major hurdle in the chamber.

The Assembly Public Safety Committee advanced the legislation, sponsored by Sen. Scott Wiener (D), in a 5-3 vote.

This comes one day after the senator held a rally with military veterans, law enforcement and health officials to build support for the proposal.

SB 519 would remove criminal penalties for possessing or sharing numerous psychedelics—including psilocybin mushrooms, DMT, ibogaine, LSD and MDMA—for adults 21 and older.

The sponsor supported a committee amendment that removed ketamine from the list of psychedelics included in the reform. That’s in addition to a series of technical revisions that were made to the legislation.

The full Senate approved the bill earlier this month, and it still has two more Assembly panel stops—the Public Health and Appropriations Committees—before moving to the floor and then, potentially, to the governor’s desk.

“Under SB 519, we will no longer arrest people and incarcerate them for the simple personal possession of psychedelics for personal or shared use,” Wiener told the committee on Tuesday. “That’s really the question here: Do we believe that we should be arresting someone because they possess psychedelics for personal use? I don’t think we should. Frankly, I think most people don’t think we should be doing that.”

Wiener has described its prospects going forward as “very challenging,” but he made the case at Monday’s press event that it is a necessary policy change to advance mental health reform and end criminalization.

Under the measure, the state Department of Public Health would be required to establish a working group “to study and make recommendations regarding possible regulatory systems that California could adopt to promote safe and equitable access to certain substances in permitted legal contexts.” Those recommendations would be due by January 1, 2024.

For psilocybin specifically, the legislation would repeal provisions in California statute that prohibit the cultivation or transportation of “any spores or mycelium capable of producing mushrooms or other material” that contain the psychoactive ingredient.

The bill originally included record sealing and resentencing provisions for people previously convicted of psychedelics possession offenses, but that language was removed in its last committee stop prior to the Senate floor vote as part of an amendment from the sponsor.

United Nations calls for global ban on cannabis advertising

United Nations calls for global ban on cannabis advertising

United Nations cannabis advertising law

The United Nations on Thursday called for a global ban on all advertising that promotes cannabis products, in a move that it said could mimic its efforts to lead a global effort to limit tobacco marketing and use.

The UN can only recommend such a move, and it would be up to member nations to implement and enforce any kind of advertising ban.

A comprehensive ban on advertising, promoting and sponsoring cannabis would ensure that public health interests prevail over business interests,” the UN’s Office on Drugs and Crime wrote in its annual World Drug Report.

“Such a ban would need to apply across all jurisdictions,” the global agency added.

The agency noted in its report that pot products “have almost quadrupled in strength in the United States of America and have doubled in Europe in the last two decades.”

Even as the products have become more potent over the last 20 years, the percentage of adolescents who view the drug as harmful has decreased by as much as 40 percent over the past 20 years, the UNODC said.

It added that marijuana can lead to mental health disorders in long-term, heavy users.

“Aggressive marketing of cannabis products with a high THC content by private firms and promotion through social-media channels; can make the problem worse,” the UN officials wrote in their report.

The UNODC did not specify how such a ban would work, but noted that “the measures could work in a way similar to the provisions of the WHO Framework Convention on Tobacco Control.”

NFL Paying $1 Million to Fund Cannabis Research

NFL Paying $1 Million to Fund Cannabis Research

the NFL is funding cannabis research

After putting out a formal request for information about pain management alternatives to opioids in February, the NFL and NFL Players Association are providing $1 million to fund research on cannabinoids and pain relief, according to Front Office Sports.

“While this represents a different stance by the league, it’s still conservative compared to players who use cannabis or cannabis products – particularly CBD, a non-psychoactive cannabinoid that has gained mainstream acceptance,” per FOS.

The NFL did shorten the window during which it tests players for THC and raise the threshold to trigger a positive test last season, but players can still be fined several weeks’ salary and be forced to join a treatment program for testing positive for the inhibiting chemical in marijuana. Though it shouldn’t be the case, that currently makes the use of CBD – which both past and current players swear by – somewhat of a grey area in the NFL.

In the February information request, the NFL-NFLPA’s pain management committee said it was looking for information including:

  1. The potential therapeutic role of medications and non-pharmacological interventions that are considered to be alternatives to opioids in routine pain management of NFL players. Medications may include, but are not limited to, cannabinoids such as cannabidiol (“CBD”).
  2. The impact of cannabis or cannabinoids on athletic performance in NFL players.
  3. The potential therapeutic role of medications and non-pharmacological interventions that are considered adjunctive to routine post-surgical orthopedic pain management in NFL football players.

Nothing is for certain, but it seems like a good assumption the new funding will be used to delve into some of the areas mentioned above.

“This isn’t an NFL or a sports issue; this is a societal issue,” the NFL’s chief medical officer Allen Sills told Bloomberg.

Washington State Announces ‘Joint for Jabs’ Covid Vaccine Program

Washington State Announces ‘Joint for Jabs’ Covid Vaccine Program

Washington state joint for jabs

A vaccine can now get you some pre-rolled bud in the state of Washington.

The state’s liquor and cannabis board announced on Monday that in an effort to support coronavirus vaccinations, it will temporarily allow state-licensed cannabis retailers to give a free joint to adults who get their first or second dose at a vaccine clinic at one of the retail locations.

Call it the latest bounty in an ever-expanding list of incentives popping up across the country meant to push Americans to get their shots. “Joints for jabs” and similar campaigns have been around for months, with cannabis activist groups and local dispensaries offering joints for vaccinations. Now, a state is promoting the program.

Health experts have repeatedly said vaccine demand would wane and each new shot in an arm would be harder to achieve either because of hesitancy, access or logistical challenges for the population left unvaccinated.

“Since the start of the pandemic itself, we’ve always had about a quarter of the population that’s been like, ‘Uh, I really don’t know,’ ” said Rupali Limaye, a behavioral and social scientist that studies vaccine hesitancy at the Johns Hopkins Bloomberg School of Public Health. “It makes sense we’re at this place where we’re having to persuade people to get the vaccine.”

She said it was “pretty fascinating” to see how creative states can get with their incentives, especially as health officials and local leaders figure out how to tailor messaging, and incentives, around different segments of the population. Officials in New Jersey and D.C., for example, said they were targeting younger populations with campaigns offering free beer for shots.

Washington Gov. Jay Inslee (D) also announced a suite of other vaccine incentives last week — including lottery prizes, sports tickets and game systems — to help encourage unvaccinated residents.

“For some people it may be enough to say, ‘You get a doughnut.’ For others, they may need something more, like a college scholarship,” Limaye said. “To me, it matches the general principles of how we should focus on behavioral science, by meeting people where they are.”

Vaccination incentive campaigns have ballooned in recent weeks — getting a vaccine can make you a millionaire, or at least get you a free beer. These marketing strategies from local leaders and corporations have taken on added urgency as vaccination levels across the country fall. The Biden administration has itself pushed an array of incentives to get more people vaccinated ahead of the Fourth of July, a deadline set by the president to get 70 percent of adults at least partially vaccinated.

In recent days, the nation’s daily average doses has dropped to under a million, down more than two-thirds from a mid-April peak of more than 3.3 million daily average doses, according to data tracked by The Washington Post. The lag puts Biden’s national goal at risk, even as more than a dozen states have already reached the 70 percent milestone.

 

Read Full Story on Washington Post